Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its results for the second quarter (Q2) ended September 30, 2012. For Q2 ended September 30, 2012, Glenmark’s consolidated revenue was at $227.89 million as against $230.74 million an increase of 18.93 per cent.
Excluding out-licensing income received in Q2 of the previous financial year, Glenmark’s consolidated revenue for the second quarter grew by 33.96 per cent. Revenue from the generics business was at $104.97 million, as against $87.23 million, a growth of 44.95 per cent. The specialty formulation business excluding out-licensing revenue was at $ 121.64 million as against $112.24 million for the corresponding previous quarter, recording a growth of 30.45 per cent.
Net profit was Rs 1567.52 million as compared to Rs. 782.75 million for for the previous corresponding quarter, recording an increase of 100.2 per cent.
“We continue on our high growth trajectory with both the generics and specialty business registering good growth across geographies. The growth from markets particularly the US, India and Russia have been particularly exceptional,” said Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals Limited.
EP News Bureau